Basic Information
| LncRNA/CircRNA Name | circCDR1-AS |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | qPCR |
| Sample | lung adenocarcinoma tissues and cell lines |
| Expression Pattern | up-regulated |
| Function Description | CDR1-AS was highly expressed in PTX and CDDP resistant LUAD tissues and cell line (A549/CR). Silence of CDR1-AS re-sensitized A549/CR cells to PTX and CDDP. CDR1-AS was an independent prognostic biomarker for LUAD patients. |
| Pubmed ID | 31881486 |
| Year | 2020 |
| Title | Circular RNA CDR1-AS contributes to pemetrexed and cisplatin chemoresistance through EGFR/PI3K signaling pathway in lung adenocarcinoma |
External Links
| Links for circCDR1-AS | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |